Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| RES-A108 | Human | resDetect™ Human Fibronectin ELISA Kit (Residue Testing) | |||
| GMP-FINH18 | Human | GMP Recombinant Human Fibronectin fragment |  |
|
|
| FIN-H5116 | Human | Recombinant Fibronectin fragment, premium grade |  |
|
|
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) immobilized on SA Chip can bind GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) with a typical affinity constant of 0.799 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Biotinylated Human ITGA5&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82Wa) immobilized on SA Chip can bind GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) with a typical affinity constant of 35.7 nM as determined in a SPR assay (Biacore 8K) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Eye Diseases; Venous Thrombosis; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Onfekafusp alfa | Phase 3 Clinical | Philogen Spa | Solid tumours; Glioblastoma; Sarcoma; Breast Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Glioma; Lung Neoplasms; Melanoma | Details | |
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Adenomatous Polyposis Coli; Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Radretumab | L19-I131; L19-SIP; I-L19-SIP; I-131-L19-SIP; 131I-L19-SIP; L19-131-I; 131I-radretumab; 131I-L19SIP; L19-131I | Phase 2 Clinical | Philogen Spa | Hematologic Neoplasms; Hodgkin Disease; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| PYX-201 | PYX-201 | Phase 2 Clinical | Pfizer Inc | Solid tumours | Details |
| F8-IL10 | F8-IL10; PF-06687234 | Phase 2 Clinical | Philogen Spa | Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative | Details |
| 177Lu-B5-IgG4 | 177-Lu-B5-IgG4 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
